Talphera Inc (TLPH)

Currency in USD
0.4325
+0.0122(+2.90%)
Closed·
0.4311-0.0014(-0.32%)
·
TLPH Scorecard
Full Analysis
Significant return over the last week
TLPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.40710.4400
52 wk Range
0.38001.1900
Key Statistics
Prev. Close
0.4325
Open
0.415
Day's Range
0.4071-0.44
52 wk Range
0.38-1.19
Volume
154.63K
Average Volume (3m)
334.28K
1-Year Change
-52.47%
Book Value / Share
0.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TLPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.2500
Upside
+651.45%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Talphera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Talphera Inc Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California.

Employees
13

Talphera Inc Earnings Call Summary for Q1/2025

  • Talphera reduced Q1 2025 cash operating expenses to $2.9M from $4.2M in Q1 2024; expects 2025 cash operating expenses of $17-19M
  • Company focusing on nephro CRRT trial with FDA-approved changes; aims to complete trial in 2025 and target NIAID approval in 2026
  • Financing strategy includes three tranches; cash balance $5.4M as of March 31, 2025; pro forma cash balance $9.8M after financing
  • Stock price increased 1.96% in aftermarket trading to $0.52; InvestingPro analysis suggests stock is undervalued despite rapid cash burn
  • Plans to activate 5 additional clinical trial sites by mid-year to enhance patient enrollment; addressing enrollment challenges at legacy sites
Last Updated: 14/05/2025, 22:16
Read Full Transcript

Compare TLPH to Peers and Sector

Metrics to compare
TLPH
Peers
Sector
Relationship
P/E Ratio
−0.8x−2.4x−0.5x
PEG Ratio
−0.020.000.00
Price/Book
1.6x−0.1x2.6x
Price / LTM Sales
328.4x1.5x3.3x
Upside (Analyst Target)
-76.7%40.3%
Fair Value Upside
Unlock1.2%4.7%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.2500
(+651.45% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.10 / -0.14
Revenue / Forecast
27.00K / --
EPS Revisions
Last 90 days

TLPH Income Statement

People Also Watch

20.40
SRPT
+8.51%
0.4262
OTRK
-3.14%
0.400
ADIL
+1.27%

FAQ

What Stock Exchange Does Talphera Trade On?

Talphera is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Talphera?

The stock symbol for Talphera is "TLPH."

What Is the Talphera Market Cap?

As of today, Talphera market cap is 8.87M.

What Is Talphera's Earnings Per Share (TTM)?

The Talphera EPS (TTM) is -0.45.

From a Technical Analysis Perspective, Is TLPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Talphera Stock Split?

Talphera has split 1 times.

How Many Employees Does Talphera Have?

Talphera has 13 employees.

What is the current trading status of Talphera (TLPH)?

As of 14 Aug 2025, Talphera (TLPH) is trading at a price of 0.43, with a previous close of 0.43. The stock has fluctuated within a day range of 0.41 to 0.44, while its 52-week range spans from 0.38 to 1.19.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.